TWI767903B - 用於治療茲卡病毒感染之方法及組合物 - Google Patents

用於治療茲卡病毒感染之方法及組合物 Download PDF

Info

Publication number
TWI767903B
TWI767903B TW106107257A TW106107257A TWI767903B TW I767903 B TWI767903 B TW I767903B TW 106107257 A TW106107257 A TW 106107257A TW 106107257 A TW106107257 A TW 106107257A TW I767903 B TWI767903 B TW I767903B
Authority
TW
Taiwan
Prior art keywords
zika virus
day
compound
subject
dose
Prior art date
Application number
TW106107257A
Other languages
English (en)
Chinese (zh)
Other versions
TW201731515A (zh
Inventor
亞拉格達 巴布
普瑞凡 科頓
桑塔 班提亞
Original Assignee
美商百歐克斯製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商百歐克斯製藥公司 filed Critical 美商百歐克斯製藥公司
Publication of TW201731515A publication Critical patent/TW201731515A/zh
Application granted granted Critical
Publication of TWI767903B publication Critical patent/TWI767903B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW106107257A 2016-03-06 2017-03-06 用於治療茲卡病毒感染之方法及組合物 TWI767903B (zh)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US201662304317P 2016-03-06 2016-03-06
US62/304,317 2016-03-06
US201662324180P 2016-04-18 2016-04-18
US62/324,180 2016-04-18
US201662368111P 2016-07-28 2016-07-28
US62/368,111 2016-07-28
US201662370697P 2016-08-03 2016-08-03
US62/370,697 2016-08-03
US201662411867P 2016-10-24 2016-10-24
US62/411,867 2016-10-24
US201662414466P 2016-10-28 2016-10-28
US62/414,466 2016-10-28
US201762462852P 2017-02-23 2017-02-23
US62/462,852 2017-02-23

Publications (2)

Publication Number Publication Date
TW201731515A TW201731515A (zh) 2017-09-16
TWI767903B true TWI767903B (zh) 2022-06-21

Family

ID=59789791

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106107257A TWI767903B (zh) 2016-03-06 2017-03-06 用於治療茲卡病毒感染之方法及組合物

Country Status (9)

Country Link
US (3) US10512649B2 (https=)
EP (1) EP3426659A4 (https=)
JP (1) JP7046015B2 (https=)
AU (1) AU2017229105B2 (https=)
CA (1) CA3016588A1 (https=)
MA (1) MA43812A (https=)
MX (1) MX381542B (https=)
TW (1) TWI767903B (https=)
WO (1) WO2017155886A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020171080A1 (ja) * 2019-02-18 2020-08-27 株式会社栄養・病理学研究所 ブタにおけるｔ細胞の活性化度を評価する方法、ブタにおけるｔ細胞活性化を評価する剤、ブタｔ細胞活性化剤をスクリーニングする方法、ブタの病原体感染を検査する方法、及びハイブリドーマ

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150051230A1 (en) * 2010-10-15 2015-02-19 Biocryst Pharmaceuticals, Inc. Methods and Compositions for Inhibition of Polymerase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985848A (en) 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
US6228741B1 (en) 1998-01-13 2001-05-08 Texas Instruments Incorporated Method for trench isolation of semiconductor devices
US7388002B2 (en) 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
US7098334B2 (en) 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
US7560434B2 (en) 2004-06-22 2009-07-14 Biocryst Pharmaceuticals, Inc. AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
NZ575365A (en) 2006-09-07 2012-02-24 Ind Res Ltd Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases
CA2663618A1 (en) 2006-09-11 2008-06-05 Southern Research Institute Azole nucleosides and use as inhibitors of rna and dna viral polymerases
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150051230A1 (en) * 2010-10-15 2015-02-19 Biocryst Pharmaceuticals, Inc. Methods and Compositions for Inhibition of Polymerase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
網路文獻 CDC， Flaviviridae， 網址：https://www.cdc.gov/vhf/virus-families/flaviviridae.html (Page last reviewed: June 18, 2013) *
網路文獻 CDC， Flaviviridae， 網址：https://www.cdc.gov/vhf/virus-families/flaviviridae.html (Page last reviewed: June 18, 2013) 。

Also Published As

Publication number Publication date
AU2017229105A1 (en) 2018-10-11
MX381542B (es) 2025-03-04
CA3016588A1 (en) 2017-09-14
EP3426659A1 (en) 2019-01-16
US20210186976A1 (en) 2021-06-24
JP7046015B2 (ja) 2022-04-01
US10512649B2 (en) 2019-12-24
US20190083496A1 (en) 2019-03-21
WO2017155886A1 (en) 2017-09-14
AU2017229105B2 (en) 2021-08-12
US10933066B2 (en) 2021-03-02
EP3426659A4 (en) 2019-12-25
JP2019507195A (ja) 2019-03-14
US11975003B2 (en) 2024-05-07
MX2018010707A (es) 2019-03-28
US20200085830A1 (en) 2020-03-19
TW201731515A (zh) 2017-09-16
MA43812A (fr) 2018-11-28

Similar Documents

Publication Publication Date Title
JP5902698B2 (ja) ポリメラーゼの阻害のための方法および組成物
Zhao et al. Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening
WO2022035911A2 (en) Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent
EP2893936B1 (en) Glutaryl histamine for the treatment and prophylaxis of diseases caused by (+)rna-containing viruses
US20240261313A1 (en) Kit for preventing or treating filovirus and flavivirus diseases
CN113350330A (zh) 杨梅素类化合物在制备防治新冠肺炎药物中的应用
Oxford et al. New millennium antivirals against pandemic and epidemic influenza: the neuraminidase inhibitors
US11975003B2 (en) Methods and compositions for treatment of Zika virus infection
CN104203228A (zh) 具有抗黄病毒的抗病毒活性的组合物
Wutzler et al. Neuraminidase inhibitors in the treatment of influenza A and B–overview and case reports
US12472197B2 (en) Methods, compositions, and dosing regimens for treatment of SARS-CoV-2 infections
KR102590438B1 (ko) Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 예방 또는 소독용 조성물
CN113440527B (zh) 萘酚喹或含萘酚喹的组合制剂在抗冠状病毒中的应用
EP4275683A1 (en) Antiviral pharmaceutical composition comprising steroid sulfatase inhibitor
TWI800146B (zh) 魚針草酸用於製備抑制新型冠狀病毒與變異株等感染與複製之醫藥組合物的用途
Yang et al. Norovirus: Clinical Findings and Pharmaceutical Developments
Oxford et al. Specific antiviral therapy of respiratory viruses
HK1191565B (en) Methods and compositions for inhibition of polymerase